EOLS

EvolusA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

30%

Probability

Target price

$15.00

Analysis reference price unavailable

Analysis 2026-09-11 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$10.50

Analysis reference price unavailable

Analysis 2026-09-11 · RankAlpha Sentiment Codex

B-

Bear case

20%

Probability

Target price

$5.50

Analysis reference price unavailable

Analysis 2026-09-11 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-09-11

AI commentary

Primary-source operating tone remains constructive after the August Q2 release, but subsequent evidence is thin. The $7.91 September 10 anchor is below the CEO's September 2 sale price and well below the unverified-count $15 analyst median. Reliable social coverage, options skew, short interest, employee sentiment and post-print analyst revisions are unavailable; unavailable numeric sentiment fields are represented as zero rather than measured neutral readings. This remains a cautious monitoring thesis, not a high-conviction rerating call.

RankAlpha Sentiment Codex - 2026-09-11

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-12-31catalystDelivery against raised 2026 outlookHigh impact

Evolus reported Q2 global net revenue of $84.1 million, up 21%, and a third consecutive quarter of positive adjusted EBITDA. Management raised 2026 revenue guidance to $330 million-$337 million and adjusted gross-margin guidance to 67.0%-67.5%; execution against these targets is the principal near-term rerating test [#SEC-8K-2026-08-05].

2027-03-31eventEvolysse adoption and portfolio cross-sellingHigh impact

Q2 injectable-gel revenue reached $8.9 million, with stored earnings coverage attributing sequential growth to greater penetration, reorders and utilization. Continued adoption alongside Jeuveau would support the diversified commercial-platform thesis [#PR-EARNINGS-2026-08-06].

2030-12-31catalystInternational expansion and Profhilo developmentHigh impact

Evolus expanded its injectable portfolio through Profhilo, with anticipated U.S. commercialization in 2030, and broadened Estyme rights into Canada, Australia and New Zealand with expected commercialization in 2028. These initiatives expand the addressable portfolio but carry long-duration regulatory and execution risk [#SEC-8K-2026-08-05].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-09-11 • Updated nightlySource: Internal modelMethodology